DeutschNewstral
Article
jdsupra.com on 2016-11-14 23:30
CHMP Recommends Approval of Three Biosimilars to EMA
Related news
- EMA CHMP Recommends Grant of Marketing Authorization for Three Biosimilarsjdsupra.com
- FDA Committee Recommends Approval of Bevacizumab and Trastuzumab Biosimilarsjdsupra.com
- EMA Committee Recommends Approval for Celltrion’s Truxima (rituximab) Biosimilarjdsupra.com
- CHMP adopts positive opinions on two bevacizumab biosimilarsjdsupra.com
- EMA Recommends Blenrep, Adakveo, and Equidacent for Approval; Recommends Change in Prescription Status for Crysvita and Imfinzijdsupra.com
- EMA Releases Informational Guide on Biosimilars for Healthcare Providersjdsupra.com
- EMA Accepts Applications for Two Mylan and Biocon Biosimilarsjdsupra.com
- Biosimilars: Solicitor General Recommends Granting Certiorari in Amgen v. Sandozjdsupra.com
- Biosimilars Update -- Pfizer's Proposed Epogen®/Procrit® Biosimilar Recommended for Approvaljdsupra.com
- EMA to Launch Scientific Advice Pilot to Aid in the Development of New Biosimilarsjdsupra.com
- Celltrion Seeks EMA Approval for Avastin Biosimilarjdsupra.com
- EMA pilot project on tailored scientific advice to support new biosimilarsjdsupra.com
- Biocon Requests Withdrawal and Re-Submission of EMA Applications for it's Trastuzumab and Pegfilgrastim Biosimilarsjdsupra.com
Federal panel recommends cholesterol drug for approvalWashington Post- FDA Advisory Committee Recommends Approval of Pfizer’s EPOGEN®/PROCRIT® Biosimilarjdsupra.com
- [Webinar] Biologics and Biosimilars: Development with an Eye Towards FDA Approval - February 17th, 10:00am PST/1:00pm ESTjdsupra.com
- PEMA recommends COVID-19 Vaccine Janssen for authorization in the EUpendect.com
- EMA Recommends Denying Marketing Authorization for Prestige BioPharma’s TUZNUE and HERVELOUS (trastuzumab)jdsupra.com
- KThe Moscow Times: EMA still awaiting Sputnik V data before approvalKyivPost
- Global Biosimilars Approval and Launch Updatesjdsupra.com